Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Supplement
HIV testing services
December 2016
Position Statement
Diabetes Care2018;42(Suppl. 1):S1–S194.
Conflict, in its active or latent forms, is everywhere. The COVID-19 pandemic has demonstrated that public health emergencies can strike any country at any time. Given the universality of and interconnections between conflict, humanitarian crises,
...
and public health emergencies, practitioners trained in one sector or the other are being called upon to understand how to navigate all of these emergencies at once.
more
Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
White Paper from the National Child Traumatic Stress Network Refugee Trauma Task Force
Zanoni BC, et al. BMJ Glob Health 2016;1:e000004. doi:10.1136/bmjgh-2015-000004
The COVID-19 pandemic’s immediate costs, measured in lives lost and damaged, have been appalling and continue to rise. In addition, its effects on individuals’ livelihoods
...
and economies around the world have been deep and are likely to be long lasting. While saving lives was the near-exclusive focus during the first phase of the crisis, governments are now trying to strike a delicate balance between preventing further economic damage by reopening parts of their economies, while managing the obvious health risks of doing so.
In the international mobility and migration arenas—policy areas enormously affected by the health and economic effects of the pandemic—this reflection considers both how these fields have fared thus far and the challenges that lay ahead
more
Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018. World Health Organization.
Cochrane Systematic Review - Intervention Version published: 15 April 2020
https://doi.org/10.1002/14651858.CD011621.pub4
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements
...
for evidence-based policies.
more